OpenAlex
PricingAboutJobs
Log inGet started
Work

Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence

HTML

Year: 2014
Type: article
Source: Expert Opinion on Biological Therapy
DOI: 10.1517/14712598.2014.902929
Authors: Arrigo FG Cicero, Elisa Tartagni, Sibel Ertek
Institutions: IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna
Language: English

Topic: Lipoproteins and Cardiovascular Health
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: evolocumab, PCSK9 inhibition, LDL cholesterol lowering, statin intolerance, apolipoprotein B-100, lipoprotein(a), monoclonal antibodies, LDL receptor degradation, lipid-lowering therapy, adverse events, nasopharyngitis
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2006364971
FWCI: 3.373
Cites: 27
Cited by: 26
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security